Chris Mirabelli

Dr. Chris K.
Mirabelli is an Independent Director at Aro Biotherapeutics Co., a Managing Director at HealthCare Ventures LLC, an Executive Chairman at Flamingo Therapeutics BV, a Managing Director at Healthcare Partners IX LLC, a Managing Director at Healthcare Partners VIII LLC and a Managing Director at Healthcare Strategic Partners, LLC.
He is on the Board of Directors at Aro Biotherapeutics Co., Fredonia College Foundation, Galleon Pharmaceuticals, Inc., Theraclone Sciences, Inc., Visionary Therapeutics Corp.
and Guilford College.
Dr. Mirabelli was previously employed as a Member-Supervisory Board by Dynacure SA, an Independent Director by Trevena, Inc., a Director, President-Pharmaceutical R&D by Takeda Oncology Co., a Chairman, President & Chief Executive Officer by LeukoSite, Inc., a Senior Vice President-Research by Isis Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Anexon, Inc., a President & Director by DecImmune Therapeutics, Inc., a Chairman by Proteostasis Therapeutics, Inc., a Principal by SmithKline & French SpA, and a Chairman by Thios Pharmaceuticals, Inc. He also served on the board at Cypherpunk Technologies, Inc., Critical Therapeutics, Inc., Adheron Therapeutics, Inc., Anchor Therapeutics, Inc., Antisoma, Inc. and FoldRx Pharmaceuticals LLC.
He received his undergraduate degree from The State University of New York College at Fredonia and a doctorate degree from Baylor College of Medicine.